Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 35
2019 74
2020 107
2021 76
2022 50
2023 66
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Results by year

Filters applied: . Clear all
Page 1
CGRP and the Trigeminal System in Migraine.
Iyengar S, Johnson KW, Ossipov MH, Aurora SK. Iyengar S, et al. Headache. 2019 May;59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14. Headache. 2019. PMID: 30982963 Free PMC article. Review.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Drilon A, et al. N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653. N Engl J Med. 2020. PMID: 32846060 Free PMC article. Clinical Trial.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A, Puig L, Schäkel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Pinter A, et al. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2087-2100. doi: 10.1111/jdv.18376. Epub 2022 Jul 29. J Eur Acad Dermatol Venereol. 2022. PMID: 35766124
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, Zhu D, Pontes Filho MAG, Wu WS, Eichenfield LF. Torrelo A, et al. Br J Dermatol. 2023 Jul 7;189(1):23-32. doi: 10.1093/bjd/ljad096. Br J Dermatol. 2023. PMID: 36999560 Clinical Trial.
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Anker SD, et al. Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064. Eur J Heart Fail. 2020. PMID: 33251670 Free article. Clinical Trial.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K; BREEZE-AD4 study group. Bieber T, et al. Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.
398 results